<DOC>
	<DOCNO>NCT01192698</DOCNO>
	<brief_summary>The main goal study prevent liver allograft infection Hepatitis C virus hepatitis C positive patient undergo liver transplantation . The hypothesis patient receive ribavirin immediately transplant intravenous interferon alfa 2b anhepatic phase ( liver remove ) sustain virologic response post liver transplant .</brief_summary>
	<brief_title>Intravenous Interferon During Anhepatic Phase Liver Transplantation Prevention Recurrence Hepatitis C Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>liver transplant hepatitis c allergy interferon</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>hepatitis c</keyword>
	<keyword>liver transplant</keyword>
	<keyword>hepatitis C liver transplant</keyword>
</DOC>